Skip to content

PTC technology for predicting the efficacy of therapeutic drugs after EGFR-TKIs resistance in advanced non-small cell lung cancer

An observational study on the efficacy of PTC technology in predicting drugs response after resistance to the third-generation EGFR-TKIs in patients with advanced non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123275
Enrollment
Unknown
Registered
2026-04-23
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Observation group:none

Sponsors

Beijing Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18-75 years (including 18 and 75 years), with no gender restriction; 2.Patients with stage IIIB/IIIC or IV NSCLC who are ineligible for radical surgery or radiotherapy and have disease progression after treatment with third-generation TKIs; 3.Having at least 1 measurable lesion (according to RECIST 1.1); 4.Patients can tolerate conventional drug therapies within the screening scope of PTC and have no severe underlying diseases such as cardiopulmonary diseases; 5.Sufficient fresh samples for cell culture can be obtained, and lung biopsy is planned in routine diagnosis and treatment. Priority is given to primary pulmonary lesions;alternatively, malignant pleural effusion, superficial lymph nodes, subcutaneous metastases, intrapulmonary metastases, hepatic metastases, etc. can also be selected; 6.ECOG performance status = 2; 7.Expected survival time of no less than 6 months; 8.Subjects (or their legal representatives) understand and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of other previously diagnosed malignant tumors; 2.Patients with uncontrolled comorbidities, including but not limited to: symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, hepatic insufficiency, renal insufficiency, uncontrolled blood glucose due to diabetes, arrhythmia, mental illness or social conditions, etc. 3.Patients with known allergies to the ingredients of the drugs used; 4.Other circumstances deemed inappropriate for participation in the study by the researcher.

Design outcomes

Primary

MeasureTime frame
Objective response rate,ORR;

Secondary

MeasureTime frame
progression-free survival;

Countries

China

Contacts

Public ContactYuyan Wang

Beijing Cancer Hospital

wangyuyan1219@aliyun.com+86 10 8819 6456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026